Zhejiang Shapuaisi Pharmaceutical (603168.SH): Olodaterol hydrochloride eye drops obtained drug registration certificate
Shapuaisi (603168.SH) announced that the company has received approval from the National Medical Products Administration for the issuance of hydrochloride...
Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that the company has received the Drug Registration Certificate for Olopatadine Hydrochloride Eye Drops approved and issued by the National Medical Products Administration. The approved Olopatadine Hydrochloride Eye Drops are used to treat eye itching related to allergic conjunctivitis.
Related Articles
"Too good" turns into bad news? Oracle Corporation (ORCL.US) stock price plunges by approximately 6.9% after issuing very optimistic guidance, marking its worst single-day performance since January.
Overnight US stocks | Three major indices closed higher, with Tesla, Inc. (TSLA.US) rising by 2.46%. Gold plummeted from a high position.
Trump declared that he will lower the price of popular weight loss drugs to $150 per month. Hims & Hers Health (HIMS.US) saw its stock price plummet by over 15%.
"Too good" turns into bad news? Oracle Corporation (ORCL.US) stock price plunges by approximately 6.9% after issuing very optimistic guidance, marking its worst single-day performance since January.
Overnight US stocks | Three major indices closed higher, with Tesla, Inc. (TSLA.US) rising by 2.46%. Gold plummeted from a high position.
Trump declared that he will lower the price of popular weight loss drugs to $150 per month. Hims & Hers Health (HIMS.US) saw its stock price plummet by over 15%.
RECOMMEND
